Xilio Therapeutics (XLO) Preferred Stock Liabilities (2020 - 2021)

Xilio Therapeutics has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $100.2 million for Q3 2021.

• Preferred Stock Liabilities for Q3 2021 came in at $100.2 million, up 382.9% year-over-year; the trailing twelve-month figure through Sep 2021 was $100.2 million (up 382.9% YoY), and the FY2020 annual result was $7.3 million, changed N/A from the prior year.
• Preferred Stock Liabilities came in at $100.2 million for Q3 2021 at Xilio Therapeutics, up from $7.3 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $100.2 million in Q1 2021 to a low of $7.3 million in Q4 2020.